CAS: 1032568-63-0; 2-Amino-N-(7-Methoxy-8-(3-Morpholinopropoxy)-2,3-Dihydroimidazo[1,2-C]Quinazolin-5-yl)Pyrimidine-5-Carboxamide

上下游产品

2-amino-pyrimidine-5-carboxylic acid 7-methoxy-8-[3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine 4-(benzyloxy)-3-methoxy-2-nitrobenzaldehyde 3-(benzyloxy)-6-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxyaniline

📜3-Methoxy-4-[3-(Morpholin-4-yl)Propoxy]-2-Nitrobenzaldehyde置于4-二甲氨基吡啶,C9H19N3*clh,5% Pd-1%fe/c,氢气,Potassium Carbonate,三乙胺体系中,用 乙醇,二氯甲烷,N,N-二甲基甲酰胺 用作溶剂,-5.0~75.0 °C,10.0 Mpa 条件下,反应 47.92H,反应生成库潘尼西
参考文献: Synthesis Of Copanlisib And Its Dihydrochloride Salt[fr] Synthèse De Copanlisib Et De Son Sel Dichlorhydrate
标题: Synthesis Of Copanlisib And Its Dihydrochloride Salt[fr] Synthèse De Copanlisib Et De Son Sel Dichlorhydrate
摘要:本发明涉及一种制备科帕利西布和科帕利西布盐酸二水合物的新方法,涉及新的中间化合物,以及利用这些新的中间化合物制备科帕利西布的用途.

专利信息

专利号:US-11649285-B2
优先权日:2016-08-03
标题 :Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
发明人：KALABOKIS VASSILIOS; WANG JINGHUA; WU GUOPING; BAZAN JOSE FERNANDO; VALLEY CHRISTOPHER CARLIN
权利人:BIO TECHNE CORP
摘要:The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

专利号:US-10494372-B2
优先权日:2014-11-07
标 题 :Synthesis of copanlisib and its dihydrochloride salt
发明人：PETERS JAN-GEORG; RUBENBAUER PHILIPP; GÖTZ DANIEL; GROSSBACH DANJA; MAIS FRANZ-JOSEF; SCHIRMER HEIKO; STIEHL JUERGEN; LOVIS KAI; LENDER ANDREAS; SEYFRIED MARTIN; ZWEIFEL THEODOR; MARTY MAURUS; WEINGÄRTNER GÃœNTER
权利人:Bayer Pharma AG
摘要:The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.

专利号:US-10035803-B2
优先权日:2014-11-07
标 题:Synthesis of copanlisib and its dihydrochloride salt
发明人：PETERS JAN-GEORG; STIEHL JÃœRGEN; LOVIS KAI
权利人:Bayer Pharma AG
摘要:The present invention relates to a novel method of preparing copanlisib, and copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib.

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-2022118123-A1
优先权日:2019-02-22
标 题 :Combination of ar antagonists and targeted thorium conjugates
发明人：HAMMER STEFANIE; HAGEMANN URS BEAT; HAENDLER BERNARD; LEJEUNE PASCALE; ZITZMANN-KOLBE SABINE; SCHATZ CHRISTOPH; KARLSSON JENNY
权利人:BAYER AG; BAYER AS
摘要:The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.

专利号:US-12390420-B1
优先权日:2024-10-22
标题 :Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof
发明人：EGUCHI MASAKATSU
权利人:BRYET US INC
摘要:The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.